导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.52% | 752/4773 |
| 近一周 | -2.52% | 2450/5462 |
| 近一月 | -3.83% | 2002/5421 |
| 近一季 | -4.46% | 1639/5209 |
| 近半年 | 0.31% | 1175/4920 |
| 近一年 | 14.53% | 723/4366 |
| 近两年 | 91.35% | 675/2954 |
| 近三年 | 60.75% | 434/2253 |
| 成立以来 | 199.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.36% 1304/4961 |
20.21% 1245/5312 |
- - |
- - |
| 2025 | 36.05% 961/4813 |
4.12% 992/3635 |
5.18% 639/4076 |
23.09% 1581/4524 |
0.92% 1658/4813 |
| 2024 | 11.59% 1313/3463 |
-1.46% 1230/2808 |
-2.24% 1161/3014 |
13.41% 2170/3129 |
2.14% 981/3463 |
| 2023 | -6.04% 805/2656 |
5.29% 804/2280 |
-3.63% 849/2385 |
-3.23% 874/2515 |
-4.31% 960/2655 |
| 2022 | -19.99% 921/2207 |
-13.88% 859/1919 |
4.23% 1034/2016 |
-9.35% 271/2113 |
-1.66% 1723/2208 |
| 2021 | 31.76% 62/1822 |
6.09% 100/1255 |
15.31% 230/1330 |
9.20% 142/1466 |
-1.36% 1359/1822 |
| 2020 | 40.95% 298/1250 |
-3.76% 319/1028 |
19.64% 294/1067 |
16.47% 150/1164 |
5.09% 808/1184 |
| 2019 | - - |
- - |
-5.64% 474/788 |
0.75% 471/850 |
8.24% 333/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博道中证500增强C VS. 长安沪深300非周期A(740101) |